PRODUCT

Follistatin 344

No short description available.

Molecular Info

Chain Length:344 amino acids (precursor); 315 amino acids (circulating form)
Sequence Type:Glycoprotein with follistatin domains
Molecular Weight:~37,800 Da (FS-315 mature form)
Amino Acid Sequence:Full sequence available in UniProt P19883
Modification:FS-344 precursor cleaved to FS-315, which includes C-terminal acidic tail that reduces cell surface binding

Research Indications

Musclegrowth

effective

Myostatin Inhibition
Blocks myostatin from binding to muscle cell receptors, removing natural growth suppression
Activin A Blockade
Also inhibits activin A, providing dual-action anti-catabolic effect
Satellite Cell Activation
Research suggests direct promotion of satellite cell proliferation

Recovery

effective

Muscular Dystrophy Research
Gene therapy trials show potential for Becker muscular dystrophy
Muscle Wasting Conditions
Under investigation for cachexia and sarcopenia

Interactions

IGF-1 LR3

Unknown

Both promote muscle growth through different pathways. Theoretical synergy but no studies on combination. Increased anabolic signaling may compound risks.

BPC-157

Unknown

Different mechanisms - BPC-157 promotes tissue repair while follistatin inhibits growth suppressors. No interaction data available.

TB-500

Unknown

Both involved in tissue regeneration through different pathways. No published studies on combination effects.

CJC-1295

Unknown

Some protocols combine follistatin with GH secretagogues. Different mechanisms but no safety data on combinations.

HGH

Monitor Combination

Both promote anabolic effects. Theoretical additive muscle growth but combined use increases risk of excessive growth factor stimulation. No clinical data.

Testosterone/Androgens

Monitor Combination

Androgens increase muscle mass through androgen receptors while follistatin inhibits myostatin. Combined use studied in some animal models but human data lacking.

ACE-031

Avoid Combination

Both target myostatin pathway. ACE-031 was discontinued due to vascular side effects. Combining myostatin inhibitors may increase adverse event risk.

Other Myostatin Inhibitors

Avoid Combination

Stacking multiple myostatin inhibitors provides no proven benefit and may increase risk of off-target TGF-β pathway disruption.

Dosage Protocols

Research Protocol (Anecdotal):100 mcgOnce daily
Higher Dose Protocol (Anecdotal):200 mcgOnce daily (max recommended)

Route:injectable

Reconstitution

Store lyophilized powder at -20°C until use
Add sterile/bacteriostatic water slowly down vial side
Gently swirl - do not shake vigorously as protein may denature
Solution should be clear - discard if cloudy
Use reconstituted solution within 7 days
Store reconstituted solution at 2-8°C, never freeze

Route:injectable

Follistatin 344

Resources

Categories

Company